Intellia Therapeutics Inc Stock Research

Market Summary

USD38.30+1.12

Market Closed

3.01%

NTLA Alerts

Big fall in earnings (Y/Y)
Losses in recent quarter

NTLA Stock Price

NTLA RSI Chart

NTLA Valuation

Market Cap

3.3B

Price/Earnings (Trailing)

-7.04

Price/Sales (Trailing)

64.01

Price/Free Cashflow

-9.62

NTLA Price/Sales (Trailing)

NTLA Profitability

Return on Equity

-38.38%

Return on Assets

-31.19%

Free Cashflow Yield

-10.4%

NTLA Fundamentals

NTLA Revenue

Revenue (TTM)

52.1M

Revenue Y/Y

5.59%

Revenue Q/Q

2.31%

NTLA Earnings

Earnings (TTM)

-474.2M

Earnings Y/Y

-39.6%

Earnings Q/Q

-0.16%

Price Action

52 Week Range

32.4478.58

(Low)(High)

Last 7 days

-5.5%

Last 30 days

-1.6%

Last 90 days

9.5%

Trailing 12 Months

-46.8%

NTLA Financial Health

Current Ratio

9.61

NTLA Investor Care

Shares Dilution (1Y)

16.94%

Diluted EPS (TTM)

-6.16

Peers (Alternatives to Intellia Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	298.0B	1.4B	-3.25%	8.54%	-148.7	210.43	20.37%	-37.45%
ABBV	279.9B	58.1B	4.88%	1.38%	23.64	4.82	3.30%	2.55%
REGN	87.7B	12.2B	9.61%	20.63%	20.21	7.2	-24.26%	-46.28%
VRTX	80.8B	8.9B	6.80%	24.91%	24.32	9.05	17.91%	41.84%
ALNY	23.5B	1.0B	-5.53%	16.05%	-20.81	22.69	22.88%	-32.64%
SRPT	11.5B	933.0M	2.93%	61.85%	-16.28	12.27	32.93%	-67.99%
UTHR	10.1B	1.9B	-9.77%	22.96%	13.92	5.23	14.88%	52.86%
MID-CAP
MDGL	4.2B	504.0K	-19.59%	144.55%	-14.38	2.5K	-66.53%	-22.12%
RARE	2.6B	363.3M	-18.37%	-45.49%	-3.74	7.28	3.39%	-55.81%
BPMC	2.6B	204.0M	1.49%	-34.21%	-4.68	12.78	13.30%	13.44%
MRTX	2.3B	12.4M	-15.06%	-52.42%	-3.05	181.9	-	-27.34%
SMALL-CAP
CPRX	1.7B	214.2M	4.81%	93.98%	20.42	7.92	52.10%	110.42%
MGNX	412.2M	151.9M	1.98%	-27.23%	-3.44	2.71	96.19%	40.75%
CRBP	28.6M	-	145.52%	1270.00%	-0.67	19.11	-77.61%	7.22%
CYTK	3.1M	94.6M	-20.08%	-11.44%	-0.01	0.03	34.30%	-80.65%

Financials for Intellia Therapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	1.4%	52,121,000	51,402,000	45,340,000	37,860,000	33,053,000
S&GA Expenses	1.7%	90,306,000	88,788,000	85,354,000	79,905,000	71,096,000
R&D Expenses	7.4%	419,979,000	391,106,000	354,941,000	323,626,000	229,807,000
EBITDA	-	-60,652,000	-	-	-	-
EBITDA Margin	-	-1.83	-	-	-	-
EBT Margin	-	-2.04	-	-	-	-
Net Income	-7.3%	-474,186,000	-442,016,000	-400,431,000	-368,559,000	-267,892,000
Net Income Margin	-5.8%	-9.10	-8.60	-8.83	-9.73	-
Free Cahsflow	-11.7%	-346,845,000	-310,583,000	-297,380,000	-264,228,000	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	40.2%	1,520	1,084	1,110	1,203	1,294
Current Assets	41.7%	1,217	859	895	875	769
Cash Equivalents	270.8%	524	141	148	133	123
Net PPE	5.0%	28.00	27.00	26.00	24.00	21.00
Current Liabilities	-3.5%	127	131	124	126	126
Shareholder's Equity	49.8%	1,236	825	881	954	1,040
Retained Earnings	-10.7%	-1,177	-1,063	-950	-849	-703
Additional Paid-In Capital	27.5%	2,420	1,898	1,841	1,812	1,746
Accumulated Depreciation	-	26.00	-	-	-	-
Shares Outstanding	13.7%	87.00	77.00	76.00	76.00	74.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-11.8%	-333	-298	-284	-252	-225
Share Based Compensation	12.4%	91.00	81.00	72.00	59.00	47.00
Cashflow From Investing	411.4%	160	31.00	-415	-477	-550
Cashflow From Financing	633.5%	583	79.00	724	725	737

Risks for NTLA

What is the probability of a big loss on NTLA?

100%

Probability that Intellia Therapeutics stock will be more than 20% underwater in next one year

95%

Probability that Intellia Therapeutics stock will be more than 30% underwater in next one year.

72.3%

Probability that Intellia Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NTLA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Intellia Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for NTLA

Cumulative Returns on NTLA

10.1%

5-Year Cumulative Returns

46.0%

3-Year Cumulative Returns

What are the long-term rolling returns for NTLA?

FIve years rolling returns for Intellia Therapeutics.

Annualized Returns

Which funds bought or sold NTLA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	reduced	-2.06	-562,457	882,543	-%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-23.38	-890,000	815,000	-%
2023-02-28	Voya Investment Management LLC	added	2.76	-2,192,670	3,910,330	0.01%
2023-02-27	Parallax Volatility Advisers, L.P.	added	541	654,424	872,424	-%
2023-02-24	NATIXIS	reduced	-8.38	-104,930	133,070	-%
2023-02-21	MACQUARIE GROUP LTD	reduced	-2.34	-492,000	698,000	-%
2023-02-16	AXXCESS WEALTH MANAGEMENT, LLC	reduced	-21.7	-518,469	494,531	0.04%
2023-02-15	Capital Impact Advisors, LLC	reduced	-10.45	-212,503	373,497	0.36%
2023-02-15	Utah Retirement Systems	unchanged	-	-198,034	327,966	-%
2023-02-15	Steward Partners Investment Advisory, LLC	reduced	-12.15	-60,871	73,129	-%

Latest Funds Activity

Are funds buying NTLA calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own NTLA

No. of Funds

Intellia Therapeutics News

Schedule 13G FIlings of Intellia Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	9.28%	7,810,226	SC 13G/A
Jan 25, 2023	blackrock inc.	8.7%	7,254,921	SC 13G
Feb 14, 2022	nikko asset management americas, inc.	3.70%	2,753,903	SC 13G/A
Feb 11, 2022	regeneron pharmaceuticals, inc.	4.98%	3,702,995	SC 13G/A
Feb 09, 2022	ark investment management llc	10.64%	7,916,882	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G
Feb 04, 2022	sumitomo mitsui trust holdings, inc.	3.70%	2,753,903	SC 13G/A
Feb 03, 2022	blackrock inc.	7.6%	5,620,376	SC 13G/A
Nov 26, 2021	ark investment management llc	10.40%	7,642,452	SC 13G/A

NTLA Fair Value

Intellia Therapeutics fair value in different scenarios

The table shows the Fair Value estimates for Intellia Therapeutics for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	0.05 -99.87%	0.11 -99.71%	0.32 -99.16%	0.66 -98.28%	0.99 -97.42%
Current Inflation	0.04 -99.90%	0.10 -99.74%	0.29 -99.24%	0.58 -98.49%	0.86 -97.75%
Very High Inflation	0.04 -99.90%	0.09 -99.77%	0.24 -99.37%	0.48 -98.75%	0.71 -98.15%

Historical Intellia Therapeutics Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Intellia Therapeutics

View All Filings

Date Filed	Form Type	Document
Mar 24, 2023	8-K	Current Report
Mar 03, 2023	4	Insider Trading
Mar 03, 2023	4	Insider Trading
Mar 03, 2023	4	Insider Trading
Mar 03, 2023	4	Insider Trading
Mar 03, 2023	4	Insider Trading
Mar 03, 2023	4	Insider Trading
Mar 03, 2023	4	Insider Trading
Mar 02, 2023	8-K	Current Report
Feb 23, 2023	10-K	Annual Report

Latest Insider Trading transactions for NTLA

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-02	BASTA JAMES	sold	-47,741	43.88	-1,088	evp, general counsel
2023-03-01	Hicks Derek	acquired	-	-	23,558	evp, chief business officer
2023-03-01	Lebwohl David	acquired	-	-	30,674	evp, chief medical officer
2023-03-01	Clark Eliana	acquired	-	-	30,673	evp, chief technical officer
2023-03-01	LEONARD JOHN M	acquired	-	-	91,036	president and ceo
2023-03-01	Sepp-Lorenzino Laura	acquired	-	-	29,938	evp, chief scientific officer
2023-03-01	Goddard Glenn	acquired	-	-	27,484	evp, chief financial officer
2023-03-01	BASTA JAMES	acquired	-	-	36,808	evp, general counsel
2023-01-05	Sepp-Lorenzino Laura	sold	-89,658	38.4802	-2,330	evp, chief scientific officer
2023-01-04	Hicks Derek	sold	-67,424	37.21	-1,812	evp, chief business officer

About Intellia Therapeutics

John M. Leonard

www.intelliatx.com

480

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NTLA Income Statement

2022-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Collaboration revenue	$ 52,121	$ 33,053	$ 57,994
Type of Revenue [Extensible List]	us-gaap:LicenseAndServiceMember	us-gaap:LicenseAndServiceMember	us-gaap:LicenseAndServiceMember
Operating expenses:
Research and development	$ 419,979	$ 229,807	$ 150,408
General and administrative	90,306	71,096	44,169
Total operating expenses	510,285	300,903	194,577
Operating loss	(458,164)	(267,850)	(136,583)
Other (expense) income, net:
Interest income	8,542	1,283	2,352
Loss from equity method investments	(11,079)	(1,325)	0
Change in fair value of contingent consideration	(13,485)	0	0
Total other (expense) income, net	(16,022)	(42)	2,352
Net loss	$ (474,186)	$ (267,892)	$ (134,231)
Net Loss Per Share, Basic	$ (6.16)	$ (3.78)	$ (2.40)
Net Loss Per Share, Diluted	$ (6.16)	$ (3.78)	$ (2.40)
Weighted average shares outstanding, basic	76,972	70,894	55,987
Weighted average shares outstanding, diluted	76,972	70,894	55,987
Other comprehensive loss:
Unrealized loss on marketable securities	$ (1,637)	$ (2,126)	$ (260)
Other comprehensive loss from equity method investment	(3,192)	(507)	0
Comprehensive loss	$ (479,015)	$ (270,525)	$ (134,491)

NTLA Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 523,506	$ 123,406
Marketable securities	669,116	625,282
Accounts receivable ($0.3 million and $0.1 million from related party)	3,768	2,031
Prepaid expenses and other current assets	20,407	18,584
Total current assets	1,216,797	769,303
Marketable securities - noncurrent	69,338	337,361
Property and equipment, net	27,921	20,968
Operating lease right-of-use assets	133,076	79,143
Equity method investment	32,455	58,131
Investments and other assets	40,527	29,558
Total Assets	1,520,114	1,294,464
Current Liabilities:
Accounts payable	5,154	9,653
Accrued expenses ($1.6 million and $0 million due to related party)	60,876	43,309
Current portion of operating lease liability	16,685	9,112
Current portion of deferred revenue ($19.9 million and $34.2 million from related party)	43,839	63,759
Total current liabilities	126,554	125,833
Deferred revenue, net of current portion ($0 million and $19.9 million from related party)	19,932	63,476
Long-term operating lease liability	114,018	64,911
Contingent consideration liability	24,026	0
Commitments and contingencies (Note 8)
Stockholders’ Equity:
Common stock, $0.0001 par value; 120,000,000 shares authorized; 87,103,007 and 74,485,883 shares issued and outstanding at December 31, 2022 and 2021, respectively	9	7
Additional paid-in capital	2,420,223	1,745,870
Accumulated other comprehensive income	(7,461)	(2,632)
Accumulated deficit	(1,177,187)	(703,001)
Total stockholders’ equity	1,235,584	1,040,244
Total Liabilities and Stockholders’ Equity	$ 1,520,114	$ 1,294,464